Affiliation:
1. Family Medicine & Public Health Sciences and Center of Molecular Medicine and Genetics, Wayne State University
2. Center of Molecular Medicine and Genetics, Wayne State University
3. Division of Biostatistics, Center for Devices and Radiological Health, Office Surveillance and Biometrics, FDA, USA
Abstract
Summary
With the availability of limited resources, innovation for improved statistical method for the design and analysis of randomized controlled trials (RCTs) is of paramount importance for newer and better treatment discovery for any therapeutic area. Although clinical efficacy is almost always the primary evaluating criteria to measure any beneficial effect of a treatment, there are several important other factors (e.g., side effects, cost burden, less debilitating, less intensive, etc.), which can permit some less efficacious treatment options favorable to a subgroup of patients. This leads to non-inferiority (NI) testing. The objective of NI trial is to show that an experimental treatment is not worse than an active reference treatment by more than a pre-specified margin. Traditional NI trials do not include a placebo arm for ethical reason; however, this necessitates stringent and often unverifiable assumptions. On the other hand, three-arm NI trials consisting of placebo, reference, and experimental treatment, can simultaneously test the superiority of the reference over placebo and NI of experimental treatment over the reference. In this article, we proposed both novel Frequentist and Bayesian procedures for testing NI in the three-arm trial with Poisson distributed count outcome. RCTs with count data as the primary outcome are quite common in various disease areas such as lesion count in cancer trials, relapses in multiple sclerosis, dermatology, neurology, cardiovascular research, adverse event count, etc. We first propose an improved Frequentist approach, which is then followed by it’s Bayesian version. Bayesian methods have natural advantage in any active-control trials, including NI trial when substantial historical information is available for placebo and established reference treatment. In addition, we discuss sample size calculation and draw an interesting connection between the two paradigms.
Publisher
Oxford University Press (OUP)
Subject
Statistics, Probability and Uncertainty,General Medicine,Statistics and Probability
Reference51 articles.
1. The nontruncated marginal of a truncated bivariate normal distribution;Arnold,;Psychometrika,1993
2. Likelihood ratio tests and intersection-union tests;Berger,,1997
3. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis;Calabrese,;Multiple Sclerosis Journal,2012
4. Approaches for testing non-inferiority in two-arm trial for risk ratio and odds ratio;Chowdhury,;Journal of Biopharmaceutical Statistics,2018
5. Non-inferiority testing for risk ratio, odds ratio and number needed to treat in three-arm trial;Chowdhury,;Computational Statistics & Data Analysis,2018
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献